Amphastar Pharmaceuticals, Inc. Treasury Stock, Value
Amphastar Pharmaceuticals, Inc. (AMPH) had Treasury Stock, Value of $482.60 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:TreasuryStockValue · last filed 2026-08-06
- 2026-06-30: Treasury Stock, Value $482.60M.
- 2026-03-31: Treasury Stock, Value $438.00M.
- 2025-12-31: Treasury Stock, Value $408.15M.
- 2025-09-30: Treasury Stock, Value $387.65M.
| Period end | Treasury Stock, Value |
|---|---|
| 2026-06-30 | $482.60M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $438.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $408.15M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $387.65M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $382.85M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $343.93M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $332.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | $290.76M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $255.80M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $247.40M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $247.43M 10-K · filed 2025-03-03 |
| 2023-09-30 | $247.44M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $197.44M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $197.54M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $189.52M 10-K · filed 2024-02-29 |
| 2022-09-30 | $171.46M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $156.97M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $151.28M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $150.48M 10-K · filed 2023-03-01 |
| 2021-09-30 | $137.05M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $130.96M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $125.55M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $121.81M 10-K · filed 2022-03-11 |
| 2020-09-30 | $118.42M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $114.12M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $108.49M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $97.63M 10-K · filed 2021-03-15 |
| 2019-09-30 | $83.85M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $79.46M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $78.39M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $75.48M 10-K · filed 2020-03-16 |
| 2018-09-30 | $72.90M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $65.45M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $58.23M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $50.70M 10-K · filed 2019-03-15 |
| 2017-09-30 | $44.73M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $37.17M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $28.19M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $20.03M 10-K · filed 2018-03-14 |
| 2016-09-30 | $19.11M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $18.34M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $14.88M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $10.17M 10-K · filed 2017-03-15 |
| 2015-09-30 | $5.99M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $3.06M 10-Q · filed 2015-08-13 |
| 2015-03-31 | $1.83M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $345.00K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |